Document:

RE-TRACK USA, INC.

                              SETTLEMENT AGREEMENT
                                  CONSISTING OF
              CONVERTABLE UNITS, CONSISTING OF $10,000.00 UNSECURED
              PROMISSORY NOTE, WARRANT TO PURCHASE SHARES OF COMMON
                         STOCK, ADDITIONAL COMMON STOCK
                                       AND
                       INVESTMENT REPRESENTATION AGREEMENT

THIS AGREEMENT: is made effective this ___day of February 1999, between Re-
Track USA, Inc. a Delaware Corporation (the "Company") and  ___________
("________").

                                   WITNESSETH

          WHEREAS, the parties acknowledge and agree that the Company and/or its
subsidiaries and affiliates have certain obligations outstanding in favor of the
____________ and/or its successors, assigns and designees (any reference to the
____________ herein shall include all such successors, assigns and designees of
the ____________) consisting of cash and other commitments, as defined in the
June ___, 1996 agreement (collectively the "Obligations"); and

          WHEREAS, the parties agree that the obligations as defined in the June
___, 1996 agreement are past due thus rendering the agreement in default.

          WHEREAS, the Company desires to satisfy the obligations and default as
defined in the June ___, 1996 agreement by issuing and executing this agreement
effective February ___ 1999.

          WHEREAS, ____________ is willing to accept this agreement effective
February ___, 1999 and the terms therein in full satisfaction of all obligations
contained in the June ____, 1996 agreement.

In consideration of the mutual promises contained herein, and other good and
valuable consideration, the parties hereto agree as follows:

1. CONSIDERATION AND AGREEMENT OF PURCHASE AND SALE: The company agrees to sell
to ____________, and ____________ agrees to purchase from the Company ____ Units
(the "Units") at a per Unit purchase price of $10,000.00 for an aggregate
purchase price of $_______. Each Unit will consist of (i) a $10,000.00 unsecured
promissory note in the form of Exhibit A hereto (the "Note") convertible under
certain conditions into shares of Common Stock of the Company (the "Common
Stock") and (ii) a Warrant (the "Warrant") in the form of Exhibit B hereto for
the purchase of certain shares of the Company's Common Stock. Payment for the
units is tendered by the execution of this agreement as and in full and final
satisfaction of all obligations due to ____________ under the terms and
conditions of the June ____, 1996 agreement. As consideration and as an
additional inducement to ____________ entering into this agreement the Company
agrees to issue _____ shares of the Company's common stock, ("the additional
common stock"), which when issued will be fully paid and non assessable.

<PAGE>

2. REPRESENTATIONS AND WARRANTIES OF THE COMPANY: In consideration of
____________ subscription for the Units, the Company represents and warrants to
the ____________ as follows:

(a) ORGANIZATION: The Company is a duly organized and existing corporation under
the laws of the state of Delaware.

(b) GOOD STANDING: The Company is in good standing under the laws of the state
of Delaware, and there are on proceedings or actions pending to limit or impair
any of its powers, rights, and privileges, or to dissolve it.

(c) CORPORATE AUTHORIZATION: The execution and delivery of this agreement and
the consummation of the transactions contemplated have been duly authorized by
proper corporate action of the Company.

3. REPRESENTATIONS AND WARRANTIES OF SUBSCRIBER: In consideration of the
Company's offer to sell the Units, ____________ hereby represents and warrants
to the Company as follows:

(a) INFORMATION ABOUT THE COMPANY: ____________ had the opportunity to ask
questions of and receive answers from the Company, or an agent or a
representative of the Company, concerning the terms and conditions of the
investment and the business and affairs of the Company and to obtain any
additional information necessary to verify such information and the ____________
has received such additional information concerning the Company the ____________
considers necessary or advisable in order to form a decision concerning an
investment in the Company.

(b) HIGH DEGREE OF RISK: ____________ realizes that the Units involve a high
degree of risk including the risks of receiving no return on the investment and
of losing the investment in the Company, ____________ also has paid particular
attention to and understands the following specific risk factors.

(i) LACK OF SALES AND PROFITS AND UNCERTAINTY OF A GOING CONCERN: The Company
has generated no sales and since inception has incurred considerable operating
losses. The Company's cash with which to conduct operations has been depleted
and its ability to continue as a going concern cannot be assured. No assurance
can be given that the Company will ever be profitable.

(ii) NEED FOR ADDITIONAL FINANCING: The Company's ability to continue as a going
concern is dependent upon its obtaining additional financing to support the
Company's operations and contemplated growth. The Units offered hereby, will not
generate any cash for the Company and are being offered only in satisfaction of
current obligations. The Company is currently requires additional equity capital
or debt financing to enable further expansion or to sustain operations. No
assurance can be given that the Company will be able to locate additional
capital on terms acceptable to it or at all.

                                       2

<PAGE>

(iii) PRODUCTS MAY Not BE COMMERCIALLY ACCEPTED: The Company has acquired a
disposable, retractable, safety syringe and certain other medical products, none
of which have been introduced to customers. There is no assurance that the
Company's intended customers will commercially accept the Company's products.

(iv) PATENT PROTECTION MAY BE INSUFFICIENT: Although the Company has certain
U.S. and foreign patents covering its disposable, retractable, safety syringe
and certain of the other medical products as acquired by the Company, there can
be no assurance that these patents sufficiently protect the Company's
intellectual property, that such patents will not be infringed by others or that
others will not develop substantially equivalent non-infringing technology.

(v) COMPETITION: The medical products industry and in particular that for
syringe products is highly competitive. Several firms, including Sherwood
Medical and BectonDickenson, offer disposable, safety syringes directly
competitive with the Company's products. These firms are better known and better
capitalized and have significantly greater financial resources, more experienced
organizations, and a greater number of employees than the Company.

(vi) GOVERNMENT REGULATION: The manufacturing and marketing of medical products
in the United States is regulated by the U.S. Food and Drug Administration (the
"FDA"). Although the Company has received 510k approval from the FDA for the
marketing of its disposable, retractable, safety syringe, it has not received
any such approval with respect to any of its other medical products. Compliance
with FDA regulations is time consuming and expensive and there can be no
assurance that the Company will ever receive additional approvals to market its
various medical products.

(vii) RELIANCE ON KEY PERSON: The Company is highly dependent upon the services
of Mr. Martin Kelly, the Company's President, CEO and founder. The loss of Mr.
Martin Kelly's services could have a materially adverse effect on the Company.

(viii) NEED FOR ADDITIONAL PERSONNEL: Mr. Kelly has no substantial experience in
the manufacturing or marketing of medical products. The Company intends to seek
additional qualified personnel. There is no assurance that the Company can
attract or retain any such new personnel.

(ix) PRODUCT LIABILITY CLAIMS: There can be no assurance that the Company will
not be named in a product liability lawsuit, nor that the Company will not be
held partially or fully liable in the event of such a lawsuit. The Company
currently has no product liability insurance, although it intends to seek
coverage when it commences commercial marketing of its products and if cash flow
permits. There is a risk of claims against the Company, based on product
liability or other legal theories for personal injury due to the failure of the
Company's products among other matters. Furthermore, even if the Company is
found not liable as to any such claims, it could, nevertheless expend a
considerable sum in defending itself against such claims.

                                       3

<PAGE>

(x) CONTROL BY MANAGEMENT: Mr. Kelly continues to own the majority of the
Company's Common Stock and will be in a position to control the affairs of the
Company, including the election of directors.

(xi) NO ESCROW OF PLACEMENT PROCEEDS: There is on requirement for an escrow in
connection with this agreement as there are no cash proceeds. This agreement is
in full satisfaction of all obligations due under the June ____, 1996 agreement.

(xii) NO ASSURANCE OF REPAYMENT ON NOTE OR ABILITY TO CONVERT NOTE OR EXERCISE
WARRANT: The notes included as part of the Units offered hereby are not secured
by any of the Company's assets. There is no assurance that the notes will be
repaid, when mature, or that, in the event of any bankruptcy proceeding or
liquidation of the Company investors will receive any payment on such notes. The
notes may not be converted into Common Stock, and the Warrants may not be
exercised unless and until the Company completes an initial public offering of
its common stock. The Company has no commitment form any investment banking firm
for such an offering and there is no assurance that the Company will ever
conduct a public offering.

(xiii) PATENTS AND TECHNOLOGY: The Company has acquired its technology from Safe
Tech Medical Products Inc. and Mr. Michael Haining , the inventor. (subject to a
$200,000 loan and security interest in favor of one of the Company's
shareholders). The Company has no outstanding obligations to Safe Tech Medical
Products Inc. and or Inventor, Mr. M. Haining whatsoever.

(xiv) POSSIBLE COMMISSIONS ON SALES OF UNITS: The Company is not required to pay
any commissions in connection with this agreement.

(xv) DILUTION: Purchases of the Units offered hereby will experience an
immediate substantial dilution in net tangible book value per share of common
stock from the placement price hereunder.

(xvi) NO DIVIDENDS: No Dividends have been paid on the Common Stock of the
Company. It is anticipated that profits, if any, received from operations will
be devoted to the Company's future operations.

The Company does not anticipate the payment of cash dividends on its Common
Stock in the foreseeable future, and any decision to pay dividends will depend
upon the Company's profitability at the time, cash available therefor, and other
factors. Investors who anticipate a need for immediate income from their
investment should not purchase Units offered hereby.

(c) ABILITY TO BEAR THE RISK: ____________ is able to bear the economic risk of
an investment in the Units, including the total loss of such investment.

(d) APPROPRIATE INVESTMENT: ____________ believes, in light of the information
provided herein and pursuant to paragraph 3 (a) above, that subscribing for the
Units pursuant to the terms of this agreement is an appropriate and suitable
investment for ____________.

                                       4

<PAGE>

(e) BUSINESS SOPHISTICATION: ____________ is experienced and knowledgeable in
financial and business matters, capable of evaluating the merits and risks of
purchasing securities of the Company.

(f) RESIDENCY: ____________ is a resident of the State of ______.

(g) STATUS AS AN "ACCREDITED INVESTOR": ____________ is (check all that apply):

         ___(1)   A natural person whose individual net worth, or joint net
                  worth with his or her spouse, exceeds $1,000,000.

         ___(2)   A natural person whose individual income was in excess of
                  $200,000, or whose joint income with his or her spouse was in
                  excess of $300,000, in each of the two most recent years, and
                  who has a reasonable expectation of reaching the same income
                  level for the current year.

         ___(3)   A bank, insurance company, registered investment company,
                  business development company, small business investment
                  company or employee benefit plan.

         ___(4)   A savings and loan association, credit union, or similar
                  financial institution or a registered broker or dealer.

         ___(5)   A Private business development company

         ___(6)   An organization described in Section 501 (c)(3) of the
                  Internal Revenue Code with assets in excess of $5,000,000.

         ___(7)   A corporation, Massachusetts or similar business trust, or
                  partnership with assets in excess of $5,000,000.

         ___(8)   A trust with assets in excess of $5,000,000.

         ___(9)   A director or executive officer of the Company.

         ___(10)  None of the above.

(If your status as an "Accredited Investor" is based upon other than 1,2, or 9
above, we will contact you to obtain more specific information.)

4. INVESTMENT PURPOSE IN ACQUIRING THE UNITS: ____________ and the Company
acknowledge that the Units, including the Notes, the Warrants, and the Common
Stock underlying the Warrants, have not been registered under the Securities Act
of 1933, as amended (the "Act"), or applicable state securities laws and that
such securities will be issued to Subscriber in reliance on exemptions from the
registration requirements of the Act and applicable state securities laws and in
reliance on ____________ and the Company's representations and agreements
contained herein. ____________ is subscribing to acquire the Units for the

                                       5

<PAGE>

account of ____________, for Investment purposes only and not with a view to
their resale or distribution. ____________ have no present intention to divide
his, her, or its participation with others or to resell or otherwise dispose of
all or any part of the Units. In making these representations, ____________
understands that, in the view of the Securities and Exchange Commission (the
"Commission"), exemption of the Units from the registration requirements of the
Act would not be available if not withstanding the representations of
____________ have in mind merely acquiring the Units for resale.

5. COMPLIANCE WITH SECURITIES ACT: ____________ agree that if the Units, the
Notes, the Warrants, the Common stock underlying the Warrants, or any part of
the foregoing are sold or distributed in the future, ____________ shall sell or
distribute them pursuant to the requirements of the Act and applicable state
securities laws. ____________ agree that ____________ will not transfer any part
of the Units without (1) obtaining a No Action letter from the Commission and
applicable state securities commissions, (2) obtaining an opinion of counsel
satisfactory in form and substance to the Company to the effect that such
transfer is exempt from the registration requirements under the Act and
applicable state securities laws, or (3) such registration.

6. RESTRICTIVE LEGEND: ____________ agree that the Company may place a
restrictive legend on the documents representing the Units, the Notes and the
Warrants.

7. STOP TRANSFER ORDER: ____________ agree that the Company may place a stop
transfer order with its registrar and stock transfer agent (if any) covering all
documents, or certificates representing the Units, the Notes, the Common Stock
or the Common Stock Underlying the Warrants.

8. KNOWLEDGE OF RESTRICTIONS UPON TRANSFER OF THE UNITS: ____________
understands that the Units, including the Notes, the Warrants the Common Stock
and any Common Stock issuable upon the exercise of the Warrants, are not freely
transferable and may in fact be prohibited from sale for an extended period of
time and that, as a consequence thereof, the undersigned must bear the economic
risk of an investment in the Units for an indefinite period of time and may have
extremely limited opportunities to dispose of the same. ____________ understands
the Rule 144 of the Commission permits the transfer of "restricted securities"
of the type herein involved only under certain conditions, after and including a
minimum two year holding period, (which with respect to the converted shares of
common stock and the common stock underlying the warrants, will not begin to run
until the exercise of the convertible option and the exercise of the warrants)
and the availability to the public or certain information concerning the
Company.

9. ADDITIONAL COMMON STOCK: The Company agrees to issue the additional common
stock and agrees that:

                                       6

<PAGE>

         1. ISSUANCE OF STOCK: Upon the receipt by the Company of an executed
copy of this agreement, in full satisfaction of all debts, promises, commitments
and any and all other obligations of whatsoever nature which the Company may owe
to the ____________ giving particular importance to the June ____, 1996
agreement, the Company will cause the issuance of ____ shares of its common
stock. ____________ agrees that in the event the Company attempts to complete an
initial public offering, existing shareholders may be required to enter into an
agreement with the underwriter and the Company for a further restrictive period
on the sale of such shares. ____________ agrees to any such requirement without
any form of objection.

         2. PROVISIONS GOVERNING THE SHARES: The following provisions are
applicable to the Shares:

                  (a) The Shares will not have been registered under the
Securities Act of 1933, as amended (the "1933 Act"), or registered or qualified
under any state securities laws and as such, the Shares are and will be
restricted securities as such term is defined under the Securities Act of 1933
(the 1933 Act") and the Shares will be issued in a transaction exempt from the
registration requirements of the 1933 Act and the registration or qualification
requirements of applicable state securities laws. The Shares will be and will
have been acquired by ____________ for investment purposes only and not with a
view to distribution or resale and may not be made subject to a security
interest, pledged, hypothecated, sold or otherwise transferred unless such
Shares are subsequently registered under the 1933 Act and qualified or
registered under applicable state securities laws or an exemption from
registration and qualification is available, and that, except as otherwise
provided in this Agreement, the Company is under no obligation to register or
qualify the Shares. The Company may require an opinion of counsel from
____________ prior to authorizing the registration of any transfer of the Shares
in reliance on an exemption from registration or qualification to the effect
that the transfer is exempt from such registration or qualification.
Certificates evidencing the Shares shall bear a standard form of Securities and
Exchange Commission restrictive legend and any such other legends as required by
applicable federal and state laws and the transfer agent for the Company class
of Common Stock shall be instructed to place a stop transfer order on the stock
books of the Company restricting the transfer of the Shares.

                  (b) ____________ and the Company agree to execute such other
documents and instruments as counsel for the Company reasonably deems necessary
to effect the compliance of the issuance of the Shares with federal and state
laws.

                  (c) the Company covenants and agrees that the Shares shall,
upon issuance, in accordance with the terms hereof, be legally and validly
issued and outstanding and fully-paid and non-assessable shares of Common Stock
of the Company.

10. ADDITIONAL DOCUMENTS: ____________ and the Company agree to execute such
other documents and instruments as counsel for the Company reasonably deems
necessary to effect the compliance of the issuance of the Units, Notes, Warrants
and Shares with federal and state laws.

11. RELEASE: Upon execution of this agreement the parties hereto and their
respective heirs, executors, administrators, successors, affiliates,
subsidiaries, designees, agents, representatives and assigns hereby release and
forever discharge the other party(ies) hereto and their respective present or
former subsidiaries, corporate parents, affiliates, officers, directors, agents,
employees, successors, representatives and assigns from any and all claims,

                                       7

<PAGE>

liabilities, actions, causes of action, suits, debts, agreements, controversies,
promises, damages and demands whatsoever (including, without limitation, any
that are contingent), in law or in equity, whether known or unknown, which the
parties, or any of them ever had, now have or hereafter may have against the
other party arising out of, or in connection with any act, omission,
transaction, event, agreement, whether oral or written, or for, upon, or by
reason of, any matter, cause or thing whatsoever from the beginning of the world
to the date of this Agreement.

12. BINDING EFFECT: Neither this agreement nor any interest herein shall be
assignable by ____________ without the prior written consent of the Company. The
provisions of this agreement shall be binding upon and inure to the benefit of
the parties hereto, and their respective heirs, legal representatives,
successors, and assigns.

13. REPRESENTATIONS TO SURVIVE DELIVERY: The representations, warranties, and
agreements of the Company and ____________ contained in this agreement will
remain operative and in full force and effect and will survive the payment of
the purchase price pursuant to Section 1 above and the delivery of documents
representing the Units.

14. GOVERNING LAW: This agreement shall be governed by and construed in
accordance with the laws of the State of Delaware, exclusive of its conflict of
laws rules.

IN WITNESS WHEREOF, the undersigned has hereunto affixed his, her, or its
signature.

In the Presence of:

________________________________            Mr. __________________

                                            --------------------------------
                                            BY:

                                            Address:
                                                     -----------------------

                                                     -----------------------

The Company hereby accepts the subscription evidenced by this Subscription and
Investment Representation Agreement.

In the Presence of:                         Re-Track USA, Inc.

----------------------------                -------------------------
                                            BY:  Martin Kelly, President

                                       8

<PAGE>

                       MR. __________________ INFORMATION

        ----------------------------------------------------------------
           (Please print name(s) in which the Units are to be issued)

                         ------------------------------
                                Taxpayer I.D. No.

Address:  ___________________________________________________________________

City:  ______________________________________________________________________

Telephone Number  _______________________

Check One:

____ Individual Ownership                            ____ Tenants in Common

____ Other                                           ____ Joint Tenants

                                       9

<PAGE>

                           CONVERTIBLE PROMISSORY NOTE

                                    EXHIBIT A

$_______                                                      FEBRUARY ___, 1999

         FOR VALUE RECEIVED, Re-Track USA Inc. a Delaware corporation (the
"Maker"), hereby agrees and promises to pay to the order of
______________________ (the "Holder") the principal sum of
___________________($_______) Dollars on February ____, 2001 (Two years from the
date of this Note above), together with interest on the unpaid principal balance
hereof at the rate of seven (7%) percent per annum.

         If a default occurs in the payment of principal or interest when due in
accordance with the terms and conditions of this Note, the Maker agrees to pay
the costs of collection, including reasonable attorneys' fees. This Note may be
prepaid at any time in any amount, without penalty or premium. All prepayments
or payments shall be applied against any unpaid interest and then against
principal.

         Without affecting the liability of the Maker, the Holder may, without
notice, renew or extend the time for payment or accept partial payments. No
delay or omission on the part of the Holder in exercising any right hereunder
shall operate as a waiver of such right or of any other remedy under this Note.
The Maker hereby waives presentment for payment, protest and notice of
non-payment.

         At any time during the six (6) months following the effective date of a
Registration Statement (if any) filed by the Maker with the Securities and
Exchange Commission respecting an initial public offering for cash of the
Maker's Common Stock (an "IPO"), the Holder may elect to convert all, but not
less than all, of the outstanding principal and accrued interest of this Note
into Common Stock of the Maker. The number of such shares issuable upon
conversion of this Note shall be computed by dividing (x) the outstanding
principal and interest of this Note at the time written notice as described
below is received by the Maker by (y) a conversion price computed as 2/3 of the
initial public offering price on the cover page of the Maker's Prospectus for
the IPO, rounded up to the next nearest $. 10. Any fractional share so computed
shall not be issued. The Holder may exercise the conversion rights hereunder by
giving written notice to the Maker at its principal executive offices, which
notice must be received by 5:00 PM on or prior to the date of expiration of
these conversion rights.

IN WITNESS WHEREOF, the undersigned has hereunto affixed its signature.

                                                   Re-Track USA, Inc.

___________________________                        By:__________________________
Notary Public                                           Martin Kelly, President

                                       10

<PAGE>

                                     WARRANT
                                    EXHIBIT B
                              TO PURCHASE SHARES OF
                                 COMMON STOCK OF
                               RE-TRACK USA, INC.

                                                                February ___1999

          This Certifies that, in consideration of having provided certain
private financing to Re-Track USA, Inc. a Delaware corporation (the "Company"),
Mr. ____________, (the "Warrant holder") is entitled to subscribe for and
purchase from the Company, at any time commencing on the Company's IPO Date, if
any (as defined below), and ending on or before 5:00 PM Central Time, on the
date which is two (2) years following the IPO Date, the number of shares of the
Company's Common Stock as computed below at the Purchase Price set forth herein,
subject to adjustment as hereinafter set forth.

1. DEFINITIONS For all purposes of this Warrant the following terms shall have
the following meanings:

         "COMMISSIONS" shall mean the Securities and Exchange Commission, or any
other federal agency then administering the Securities Act.

         "COMPANY" shall mean Re-Track USA, Inc. a Delaware corporation, and any
corporation which shall succeed to, or assume, the obligations of said
corporation hereunder.

         "COMMON STOCK" shall mean the shares of Common Stock of the Company.

         "IPO" shall mean an initial public offering for cash of the Company's
Common Stock conducted pursuant to a registration statement filed under the
Securities Act with the Commission.

         "IPO DATE" shall mean the effective date of the registration statement
filed by the Company with the Commission respecting an IPO.

         "NUMBER" shall mean the number of shares of Common Stock purchasable
upon exercise of this Warrant. The Number shall be computed by dividing (x)
$____________ (representing the aggregate purchase price by the initial Warrant
holder hereunder for Units of the Company issued in a private placement
conducted in 1996) by (y) a conversion price computed as 2/3 of the initial
public offering price on the cover page of the Company's Prospectus for the IPO,
rounded up to the next nearest $. 10. Any fractional portion of the Number as so
computed shall be disregarded. The Number is subject to adjustment as
hereinafter provided.

         "OTHER SECURITIES" shall mean any stock (other than Common Stock) or
other securities of the Company or any other person (corporate or otherwise)
which the Warrant holder at any time shall be entitled to receive, or shall have
received, upon the exercise of the Warrants, in lieu of or in addition to Common
Stock, or which at any time shall be issuable or shall have been issued in
exchange for or in replacement of Common Stock or Other Securities.

                                       11

<PAGE>

         "PURCHASE PRICE" shall mean 120% of the initial public offering price
on the cover page of the Company's Prospectus for an IPO. The Purchase Price is
subject to adjustment as hereinafter provided.

         "SECURITIES ACT" shall mean the Securities Act of 1993, as amended, and
the rules and regulations of the Commission thereunder, as in effect at the
time.

         "SUBSCRIPTION FORM" shall mean the subscription forms attached hereto.

         "TRANSFER" shall mean any sale, assignment, pledge, or other
disposition of any Warrants and/or Warrant Shares, or of any interest in either
thereof which would constitute a sale thereof within the meaning of Section 2(3)
of the Securities Act.

         "WARRANT SHARES" shall mean the shares of Common Stock purchased or
purchasable by the Warrant holder upon the exercise of the Warrants pursuant to
Section 2 hereof.

         "WARRANT HOLDER" shall mean the holder or holders of the Warrants or
any related Warrant Shares.

         "WARRANTS" shall mean the Warrants (including this Warrant), identical
as to terms and conditions and date, except as to the number of shares of Common
Stock for which they may be exercised, evidencing the right to purchase
initially an aggregate of ________ shares of Common Stock, and all Warrants
issued in exchange, transfer or replacement thereof

All terms used in this Warrant which are not defined in Section 1 hereof have
the meanings respectively set forth elsewhere in this Warrant.

2. EXERCISE OF WARRANT, ISSUANCE OF CERTIFICATE, AND PAYMENT FOR WARRANT SHARES.
This Warrant may not be exercised unless and until the Company completes an IPO.
The rights represented by this Warrant may be exercised at any time on or after
the IPO Date and from time to time, prior to expiration hereof, by the Warrant
holder, in whole or in part (but not as to any fractional share of Common
Stock), by: (a) delivery to the Company of a completed Subscription Form, (b)
surrender to the Company of this Warrant properly endorsed and signature
guaranteed, and (c) delivery to the Company of a certified or cashier's check
made payable to the Company in an amount equal to the aggregate Purchase Price
for the Number of shares of Common Stock being purchased, at its principal
office or agency (or such other office or agency of the Company as the Company
may designate by notice in writing to the holder hereof). The Company agrees and
acknowledges that the shares of Common Stock so purchased shall be deemed to be
issued to the holder hereof as the record owner of such shares as of the close

                                       12

<PAGE>

of business on the date on which this Warrant, properly endorsed, and the
Subscription Form shall have been surrendered and payment made for such shares
as aforesaid. Upon receipt thereof, the Company shall, as promptly as
practicable, and in any event within 15 days thereafter, execute or cause to be
executed and deliver to the Warrant holder a certificate or certificates
representing the aggregate number of shares of Common Stock specified in said
Subscription Form. Each stock certificate so delivered shall be in such
denomination as may be requested by the Warrant holder and shall be registered
in the name of the Warrant holder or such other name as shall be designated by
the Warrant holder. If this shall have been exercised only in part, the Company
shall, at the time of delivery of said stock certificate or certificates,
deliver to the Warrant holder a new Warrant evidencing the rights of such holder
to purchase the remaining shares of Common Stock covered by this Warrant. The
Company shall pay all expenses, taxes, and other charges payable in connection
with the preparation, execution, and delivery of stock certificates pursuant to
this Section 2, except that, in case any such stock certificate or certificates
shall be registered in a name or names other than the name of the Warrant
holder, funds sufficient to pay all stock transfer taxes which shall be payable
upon the execution and delivery of such stock certificate or certificates shall
be paid by the Warrant holder to the Company at the time of delivering this
Warrant to the Company as mentioned above.

3. OWNERSHIP OF THIS WARRANT. The Company may deem and treat the registered
Warrant holder as the holder and owner hereof (notwithstanding any notations of
ownership or writing made hereon by anyone other than the Company) for all
purposes and shall not be affected by any notice to the contrary, until
presentation of this Warrant for transfer as provided herein and then only if
such transfer meets the requirements of Section 5 hereof

4. EXCHANGE, TRANSFER AND REPLACEMENT. Subject to Section 5 hereof, this Warrant
is exchangeable upon the surrender hereof by the Warrant holder to the Company
at its office or agency described in Section2 hereof for new Warrants of like
tenor and date representing in the aggregate the right to purchase the Number of
shares purchasable hereunder, each of such new Warrants to represent the right
to purchase such number of shares (not to exceed the aggregate total Number
purchasable hereunder) as shall be designated by the Warrant holder at the time
of such surrender. Subject to Section 5 hereof, this Warrant and all rights
hereunder are transferable, in whole or in part, upon the books of the Company
by the Warrant holder in person or by duly authorized attorney, and a new
Warrant of the same tenor and date as this Warrant, but registered in the name
of the transferee, shall be executed and delivered by the Company upon surrender
of this Warrant, duly endorsed, at such office or agency of the Company. Upon
receipt by the Company of evidence reasonably satisfactory to it of the loss,
theft, destruction, or mutilation of this Warrant, and in the case of loss,
theft, or destruction, of indemnity or security reasonable satisfactory to it,
and upon surrender and cancellation of this Warrant, if mutilated, the Company
will make and deliver a new Warrant of like tenor, in lieu of this Warrant. This
Warrant shall be promptly canceled by the Company upon the surrender hereof in
connection with any exchange, transfer, or replacement. The Company shall pay
all expenses, taxes (other than stock transfer taxes), and other charges payable
in connection with the preparation, execution and delivery of Warrants pursuant
to this Section 4.

                                       13

<PAGE>

5. RESTRICTIONS ON TRANSFER. Notwithstanding any provisions contained in this
Warrant to the contrary, neither this Warrant nor the Warrant shares shall be
transferable except upon the conditions specified in this Section 5, which
conditions are intended, among other things, to ensure compliance with the
provisions of the Securities Act in respect of the transfer of this Warrant or
such Warrant Shares. The holder of this WARRANT AGREES THAT SUCH HOLDER WILL NOT
TRANSFER this Warrant or the related Warrant Shares (a) prior to delivery to the
Company of an opinion of counsel selected by the Warrant holder and reasonably
satisfactory to the Company, stating that such transfer is exempt from
registration under the Securities Act or (b) until registration of such Warrants
and/or Warrant Shares under the Securities Act has become effective and
continues to be effective at the time of such transfer. An appropriate legend
may be endorsed on the Warrants and the certificates of the Warrant Shares
evidencing these restrictions.

6. ANTIDILUTION PROVISIONS. The rights granted hereunder are subject to the
following:

(a) STOCK SPLITS AND REVERSE SPLITS. In case at any time after the IPO Date, the
Company shall subdivide its outstanding shares of Common Stock into a greater
number of shares (including upon a dividend made in Common Stock), the Purchase
Price in effect immediately prior to such subdivision shall be proportionately
reduced and the number of Warrant Shares purchasable pursuant to this Warrant
immediately prior to such subdivision shall be proportionately increased, and
conversely, in case at any time after the 1PO Date, the Company shall combine
its outstanding shares of Common Stock into smaller number of shares, the
Purchase Price in effect immediately prior to such combination shall be
proportionately increased and the number of Warrant Shares purchasable upon the
exercise of this Warrant immediately prior to such combination shall be
proportionately reduced. Except as provided in this paragraph (a), no adjustment
in the purchase price and no change in the number of Warrants Shares so
purchasable shall be made pursuant to this section 6 as a result of or by any
such subdivision or combination.

(b) REORGANIZATION, RECLASSIFICATION, CONSOLIDATION, MERGER, OR SALE. If any
capital reorganization or reclassification or merger of the Company with another
corporation, or the sale of all or substantially all of its assets to another
corporation, shall be effected in such a way that holders of shares of Common
Stock shall be entitled to receive Common Stock, Other Securities or assets with
respect to or in exchange for shares of Common Stock, then, as a condition of
such reorganization, reclassification, consolidation, merger or sale, lawful and
adequate provision shall be made whereby the Warrant holder shall thereafter
have the right to purchase and receive upon the basis and upon the terms and
conditions specified in the Warrants and in lieu of the shares of Common Stock
of the Company immediately there to for purchasable and receivable upon the
exercise of the Warrants such shares of Common Stock, Other Securities or assets
as may be issued or payable with respect to or in exchange for a number of
outstanding shares of Common stock equal to the number of shares of Common Stock
immediately thereto for purchasable and receivable upon the exercise of the
Warrants had such reorganization, reclassification, consolidation, merger or
sale not taken place, and in any such case appropriate provision shall be made
with respect to the rights and interests of the Warrant holder so that the
provisions of the Warrants (including, without limitation, provisions for
adjustment of the Purchase Price and of the number of shares purchasable upon
the exercise of the Warrants) shall thereafter be applicable, as nearly as may
be, in relation to any shares of Common Stock, Other Securities or assets,
thereafter deliverable upon the exercise of the Warrants.

                                       14

<PAGE>

7. NOTICES. Any notice or other document required or permitted to be given or
delivered to the Warrant holder shall be delivered or sent by certified mail to
the Warrant holder at last address shown on the books of the Company maintained
for the registry and transfer of the Warrants. Any notice or other document
required or permitted to be given or delivered to the Company shall be delivered
or sent by certified or registered mail to the principal office of the Company.

8. NO RIGHTS AS SHAREHOLDERS: LIMITATION OF LIABILITY. This Warrant shall not
entitle any holder hereof to any of the rights of a shareholder of the Company.
No provision hereof, in the absence of affirmative action by the holder hereof
to purchase shares of Common Stock, and no mere enumeration herein of the rights
or privileges of the holder hereof, shall give rise to any liability of such
holder for the Purchase Price or as a shareholder of the Company whether such
liability is asserted by the Company or by creditors of the Company.

9. GOVERNING LAW. This Warrant shall be governed by, and construed and enforced
in accordance with, the laws of the State of Delaware, exclusive of its conflict
of laws rules.

10. MISCELLANEOUS. This Warrant and any provision hereof may be changed, waived,
discharged, or terminated only by an instrument in writing signed by the party
(or any predecessor in interest thereof) against which enforcement of the same
is sought. The headings in this Warrant are for purposes of reference only and
shall not affect the meaning or construction of any of the provisions hereof

IN WITNESS WHEREOF, the Company has this Warrant to be signed by a duly
authorized officer, and to be dated as of the ____ day of February, 1999.

                                                  Re-Track USA, Inc.

___________________________                       By:__________________________
Notary Public                                          Martin Kelly, President

"THIS SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER
THE SECURITIES ACT OF 1993 (THE "1993 ACT") OR UNDER THE SECURITIES LAWS OF ANY
OTHER STATE AND MAY NOT BE TRANSFERRED WITHOUT (i) THE OPINION OF COUNSEL
SATISFACTORY TO THE COMPANY THAT SUCH TRANSFER MAY LAWFULLY BE MADE WITHOUT
REGISTRATION UNDER THE 1993 ACT OR THE SECURITIES LAWS OF ANY APPLICATION STATE;
OR (ii) SUCH REGISTRATION."

                                       15

<PAGE>

                             FULL SUBSCRIPTION FORM

To be Executed By the Registered Warrant holder if
He Desires to Exercise in Full the Within Warrant

The undersigned hereby exercises the right to purchase the __________________

shares of Common Stock covered by the within Warrant at the date of this

subscription and herewith makes payment of the sum of $_________ representing

the Purchase Price of $ ___________________ per share in effect at that date.

Certificates for such shares shall be issued in the name of and delivered to the

undersigned, unless otherwise specified by written instructions, signed by the

undersigned and accompanying this subscription.

Dated:____________________

                                        Signature:        _____________________

                                        Address:          _____________________

                                                          _____________________

                                       16

<PAGE>

                            PARTIAL SUBSCRIPTION FORM

To Be Executed by the Registered Warrant holder if He
Desires to Exercise in Part Only the Within Warrant

The undersigned hereby exercises the right to purchase ______________ shares of
the total shares of Common Stock covered by the within Warrant at the date of
this subscription and herewith makes payment of the sum of $_________________
representing the Purchase Price of $_______ per share in effect at this date.

Certificates for such shares and a new Warrant of like tenor and date for the
balance of the shares not subscribed for (if any) shall be issued in the name of
and delivered to the undersigned, unless otherwise specified by written
instructions, signed by the undersigned and accompanying this subscription.

[The following paragraph need be completed only if the Purchase Price and number
of shares of Common Stock specified in the within Warrant have been adjusted
pursuant to Section 6.]

The shares hereby subscribed for constitute __________ shares of Common Stock
(to the nearest whole share) resulting form adjustment of __________ shares of
the total of ________ shares of Common Stock covered by the within Warrant, as
said shares were constituted at the date of the Warrant.

Dated: ______________________

                                        Signature:        _____________________

                                        Address:          _____________________

                                                          _____________________

                                       17RETRAC MEDICAL, INC.

                          SECURITIES PURCHASE AGREEMENT
            CONSISTING OF A, $50,000.00 UNSECURED PROMISSORY NOTE(S),
                          SHARE(S) OF COMMON STOCK AND
                PURCHASER(S) INVESTMENT REPRESENTATION AGREEMENT

THIS SECURITES PURCHASE AGREEMENT AND NOTE HAS NOT BEEN REGISTERED UNDER THE
SECURITIES ACT OF 1933, AS AMENDED, (THE "ACT") OR ANY STATE SECURITIES LAWS AND
NEITHER THIS NOTE NOR ANY INTEREST THEREIN MAY BE OFFERED, SOLD, TRANSFERRED,
PLEDGED OR OTHERWISE DISPOSED OF EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION
STATEMENT UNDER SUCH ACT OR SUCH LAWS OR AN EXEMPTION FROM REGISTRATION UNDER
SUCH ACT AND SUCH LAWS OR AN EXEMPTION FROM REGISTRATION UNDER SUCH ACT AND SUCH
LAWS WHICH, IN THE OPINION OF COUNSEL SATISFACTORY TO THE COMPANY, IS AVAILABLE.

THIS AGREEMENT: is made effective this ____ day of _____________ 2000, between
RETRAC MEDICAL, INC. a Delaware Corporation, formerly Re-Track USA, Inc., (the
"Company") and __________________________________________ ( the "Purchaser(s)").

                               W I T N E S S E T H

In consideration of the mutual promises contained herein, and other good and
valuable consideration, the parties hereto agree as follows.

1. AGREEMENT OF PURCHASE AND SALE: The company agrees to sell to Purchaser(s),
and Purchaser(s) agree to purchase from the Company _______ Unit(s) (the
"Units") at a per Unit purchase price of $50,000.00 for an aggregate purchase
price of $_____________. Each Unit will consist of (i) a $50,000.00 unsecured
promissory note(s) in the form of Exhibit A hereto (the "Note"), which provides
for the repayment of the principal to together with interest thereon computed at
the rate of twelve percent (12%) per annum, from the date hereof until the
principal hereof and all interest thereon shall have been paid. Principal and
interest shall be payable upon the earlier of nine (9) month anniversary date
from the effective date herein or on the completion of an Initial Public
Offering of the Company's securities registered with the United States
Securities and Exchange Commission ("SEC") under the Securities Act of 1933
("Act") (the "IPO").

Purchaser Initials___________

<PAGE>

Upon repayment of this Note, the Company shall issue to the Purchaser(s) a
number of shares (the "Shares") of the Company's common stock, par value $.01,
per share ("Common Stock"), as shall be calculated by dividing the principal
amount of this Note by an amount equal to fifty percent (50%) of the public
offering price of a share of Common Stock offered in the company's initial
registered public offering under the Act.

The Shares shall be "restricted securities" as such term is defined in Rule 502
of Regulation D promulgated under the Act, shall be subject to substantial
restrictions on any resale or transfer thereof and the certificate evidencing
the Shares shall be imprinted with a restrictive legend prohibiting the transfer
of any such Shares (in form substantially similar to the restrictive legend
imprinted atop the Note). Commencing twelve months after the completion of the
IPO, the Holder shall have one demand registration right with respect to the
Shares under the Act and shall have unlimited "piggy-back" registration rights
with respect to the Shares, all at the company's expense.

Payment is due with the tender of this Securities Purchase Agreement and shall
be made payable to the Company.

2. REPRESENTATIONS AND WARRANTIES OF THE COMPANY: In consideration of
Purchaser(s) purchasing the Unit(s), the Company represents and warrants to the
Purchaser as follows:

(a) ORGANIZATION: The Company is a duly organized and existing corporation under
the laws of the state of Delaware.

(b) GOOD STANDING: The Company is in good standing under the laws of the state
of Delaware, and there are no proceedings or actions pending to limit or impair
any of its powers, rights, and privileges, or to dissolve it.

(c) CORPORATE AUTHORIZATION: The execution and delivery of this agreement and
the consummation of the transactions contemplated have been duly authorized by
proper corporate action of the Company.

3. REPRESENTATIONS AND WARRANTIES OF PURCHASER: In consideration of the
Company's offer to sell the Unit(s), Purchaser(s) hereby represent and warrant
to the Company as follows:

(a) INFORMATION ABOUT THE COMPANY: Purchaser(s) has had the opportunity to ask
questions and request information from the Company and to receive such
information and answers from the Company, or officer, agent and or
representative of the Company, concerning the terms and conditions of the
investment and the general and overall business affairs of the Company.

Purchaser Initials___________

                                       2

<PAGE>

Purchaser(s) has further obtained all such additional information necessary to
verify such received information. Purchaser(s) has received such additional
information concerning the Company that the Purchaser(s) considers necessary or
advisable in order to form a decision concerning an investment in the Company.

(b) HIGH DEGREE OF RISK: Purchaser(s) realizes that the Unit(s) involve a high
degree of risk including the risks of receiving no return on the investment and
the losing of the complete investment in the Company. Purchaser(s) has paid
particular attention to and understands the following specific RISK FACTORS.

(i) LACK OF SALES AND PROFITS AND UNCERTAINTY OF A GOING CONCERN: The Company
has generated no sales and since inception has incurred considerable operating
losses. The Company's cash with which to conduct operations has been depleted
and its ability to continue as a going concern cannot be assured. No assurance
can be given that the Company will ever be profitable.

(ii) NEED FOR ADDITIONAL FINANCING: The Company's ability to continue as a going
concern is dependent upon its obtaining additional financing to support the
Company's operations and contemplated growth. The Company currently requires
additional equity capital or debt financing to enable further expansion and or
to sustain operations. No assurance can be given that the Company will be able
to locate additional capital on terms acceptable to it or at all. No assurance
can be given that the Company will be successful in its offer to sell the units
contemplated herein.

(iii) PRODUCTS MAY NOT BE COMMERCIALLY ACCEPTED: The Company has acquired
patented safety disposable retractable safety syringe technology and certain
other medical products, none of which have been commercially introduced to
customers. There is no assurance that the Company's intended customers will
commercially accept the Company's products.

(iv) PATENT PROTECTION MAY BE INSUFFICIENT: Although the Company has certain
U.S. and foreign patents covering its safety disposable retractable syringe
technology and certain other medical products as acquired by the Company, there
can be no assurance that these patents sufficiently protect the Company's
intellectual property, that such patents will not be infringed by others or that
others will not develop substantially equivalent non-infringing technology.

(v) COMPETITION: The medical products industry and in particular that for
syringe products is highly competitive. Several firms, including Sherwood
Medical and Becton-Dickenson, offer disposable, safety syringes directly
competitive with the Company's products. These firms are better known and better
capitalized and have significantly greater financial resources, more experienced
organizations, and a greater number of employees than the Company.

Purchaser Initials___________

                                       3

<PAGE>

(vi) GOVERNMENT REGULATION: The manufacturing and marketing of medical products
in the United States is regulated by the U.S. Food and Drug Administration (the
"FDA"). Although the Company's syringe technology has received 510k approval
from the FDA for the marketing of its disposable, retractable, safety syringe,
it has not received any such approval with respect to any of its other medical
products. Compliance with FDA regulations is time consuming and expensive and
there can be no assurance that the Company will ever receive additional
approvals to market its various medical products.

(vii) RELIANCE ON KEY PERSON: The Company is highly dependent upon the services
of Mr. Thomas Sassone, the Company's President and CEO. The loss of Mr.
Sassone's services could have a materially adverse effect on the Company.

(viii) NEED FOR ADDITIONAL PERSONNEL: Mr. Sassone has no substantial experience
in the manufacturing or marketing of medical products. The Company intends to
seek additional qualified personnel. There is no assurance that the Company can
attract or retain any such new personnel.

(ix) PRODUCT LIABILITY CLAIMS: There can be no assurance that the Company will
not be named in a product liability lawsuit, nor that the Company will not be
held partially or fully liable in the event of such a lawsuit. The Company
currently has no product liability insurance, although it intends to seek
coverage when it commences commercial marketing of its products and if cash flow
permits. There is a risk of claims against the Company, based on product
liability or other legal theories for personal injury due to the failure of the
Company's products among other matters. Furthermore, even if the Company is
found not liable as to any such claims, it could nevertheless expend a
considerable sum in defending itself against such claims.

(x) CONTROL BY SHAREHOLDER: Mr. Martin Kelly owns the majority of the Company's
Common Stock and will be in a position to control the affairs of the Company,
including the election of directors.

(xi) NO ESCROW OF PLACEMENT PROCEEDS: There is no minimum or maximum number of
Unit(s) which must be sold by the Company pursuant to this agreement, and there
is no assurance that any specific number of Unit(s) will be sold. All proceeds
from the sale of the Unit(s) offered hereby will be deposited into the Company's
general business account upon receipt and will be available for immediate
corporate use without using an escrow of any kind.

(xii) NO ASSURANCE OF REPAYMENT ON NOTE: The note(s) included as part of the
Unit(s) offered hereby are not secured by any of the Company's assets. There is
no assurance that the note(s) will be repaid, when mature, or that in the event
of any bankruptcy proceeding or liquidation of the Company investors will
receive any payment on such note(s).

Purchaser Initials___________

                                       4

<PAGE>

The Company has contracted with the investment banking firm of Travis Morgan
Securities, Inc.(Travis), whereby Travis will use its best efforts to procure an
Initial Public Offering of the Company's securities registered with the United
States Securities and Exchange Commission ("SEC") under the Securities Act of
1933 ("Act"). However, there is no assurance that the Company will ever complete
the IPO.

(xiii) PATENTS AND TECHNOLOGY: The Company has acquired its technology from Safe
Tech Medical Products Inc. and Mr. Michael Haining , the inventor, (subject to a
$200,000 loan and security interest in favor of one of the Company's
shareholder's). The Company has no outstanding obligations to Safe Tech Medical
Products Inc. and or the Inventor, Mr. M. Haining, whatsoever.

(xiv) POSSIBLE COMMISSIONS ON SALES OF UNIT(S): The Company may engage one or
more broker/dealers to assist the Company in the sale of the Unit(s) offered
herein and pay a commission on such sales procured through the services of any
such placement agent or agents.

(xv) DILUTION: Purchaser(s) of the Unit(s) offered hereby will experience an
immediate substantial dilution in net tangible book value per share of common
stock from the placement price hereunder.

(xvi) NO DIVIDENDS. No Dividends have been paid on the Common Stock of the
Company. It is anticipated that profits received from operations (if any), will
be devoted to the Company's future operations. The Company does not anticipate
the payment of cash dividends on its Common Stock in the foreseeable future, and
any decision to pay dividends will depend upon the Company's profitability at
that time, cash available therefore and other factors. ANY PURCHASER(S) WHO
ANTICIPATE OR REQUIRE AN IMMEDIATE NEED FOR INCOME FROM AN INVESTMENT MADE IN
THE UNIT(S) OFFERED HEREBY SHOULD NOT PURCHASE THE UNIT(S) OFFERED HEREIN.

(xvii) USE OF PROCEEDS: The proceeds obtained by the Company from the sale of
the units offered herein will be used for a) repayment of certain short term
debt instruments b) further development of the Company's core patented
technology and c) general working capital and d) expenses associated with the
proposed IPO. The management of the Company will continue to have broad
discretion as to the application of the use of proceeds.

(xviii) LITIGATION: The Company is a party to certain litigation which it
believes is either of questionable merit or in the aggregate, immaterial to its
operations as a whole. The litigation is comprised of routine business disputes
arising out of its day to day operations.

All such actions are being vigorously defended and no one of them are expected
to result in either a damage award or significant expense to damage the day to
day operations of the Company. The Company does not believe that these cases, if
lost, would materially affect the Company's operations.

Purchaser Initials___________

                                       5

<PAGE>

(xix) DETERMINATION OF OFFERING PRICE: The offering price for the Securities
offered hereby bears no relationship to the assets, prospects, net worth of the
Company, or any recognized criteria of value and should not be considered to be
any indication of the actual value of the Company or it Securities. The offering
price of the Securities offered herein has been determined by the management of
the Company and there can be no assurance that subsequent trading if any of the
Unit(s) or the Shares will be at prices equal to or higher then the purchase
price of the securities offered herein.

(c) ABILITY TO BEAR THE RISK: Purchaser(s) can bear the economic risk of an
investment in the Unit(s), including the total loss of such investment.

(d) APPROPRIATE INVESTMENT: Purchaser(s) believes, in light of the information
provided herein and pursuant to paragraph 3 (a) above, the purchase of the
Unit(s) pursuant to the terms of this agreement is an appropriate and suitable
investment for the Purchaser(s).

(e) BUSINESS SOPHISTICATION: Purchaser(s) is experienced and knowledgeable in
financial and business matters, capable of evaluating the merits and risks of
purchasing the securities offered herein by the Company.

(f) RESIDENCY: Purchaser(s) is a resident of the State of: __________________.

(g) STATUS AS AN "ACCREDITED INVESTOR": Purchaser(s) is (check all that apply):

         ___(1)   A natural person whose individual net worth, or joint net
                  worth with his or her spouse, exceeds $1,000,000.

         ___(2)   A natural person whose individual income was in excess of
                  $200,000, or whose joint income with his or her spouse was in
                  excess of $300,000, in each of the two most recent years, and
                  who has a reasonable expectation of reaching the same income
                  level for the current year.

         ___(3)   A bank, insurance company, registered investment company,
                  business development company, small business investment
                  company or employee benefit plan.

         ___(4)   A savings and loan association, credit union, or similar
                  financial institution or a registered broker or dealer.

         ___(5)   A Private business development company

         ___(6)   An organization described in Section 501 (c)(3) of the
                  Internal Revenue Code with assets in excess of $5,000,000.

         ___(7)   A corporation, or similar business trust, or partnership with
                  assets in excess of $5,000,000.

Purchaser Initials___________

                                       6

<PAGE>

         ___(8)   A trust with assets in excess of $5,000,000.

         ___(9)   A director or executive officer of the Company.

         ___(10)  None of the above.

(If your status as an "Accredited Investor" is based upon other than 1,2, or 9
above, we will contact you to obtain more specific information.)

4. INVESTMENT PURPOSE IN ACQUIRING THE UNIT(S): Purchaser(s) and the Company
acknowledge that the Unit(s), including the Note(s) and the Shares have not been
registered under the Securities Act of 1933, as amended (the "Act"), or
applicable state securities laws. Securities issued herein will be issued to
Purchaser(s) in reliance on exemptions from the registration requirements of the
Act and applicable state securities laws and in reliance on the Purchaser(s) and
the Company's representations and agreements contained herein. Purchaser(s) is
subscribing to acquire the Unit(s) for the account of Purchaser(s) for
Investment purposes only and not with a view to their resale or distribution.

Purchaser(s) has no present intention to divide his, her, or its participation
with others or to resell or otherwise dispose of all or any part of the Unit(s).
In making these representations, Purchaser(s) understands that, in the view of
the Securities and Exchange Commission (the "Commission"), exemption of the
Unit(s) from the registration requirements of the Act would not be available if,
not withstanding the representations of Purchaser(s) if he she or it has in mind
merely acquiring the Unit(s) for resale.

5 COMPLIANCE WITH SECURITIES ACT: Purchaser(s) agrees that if the Unit(s), the
Note(s) and the Shares, or any part of the foregoing are sold or distributed in
the future, Purchaser(s) shall sell or distribute them pursuant to the
requirements of the Act and applicable state securities laws. Purchaser(s) agree
that Purchaser(s) will not transfer any part of the Unit(s) without 1) obtaining
a No Action letter from the Commission and applicable state securities
commissions, 2) obtaining an opinion of counsel satisfactory in form and
substance to the Company to the effect that such transfer is exempt from the
registration requirements under the Act and applicable state securities laws, or
3) such registration.

6 RESTRICTIVE LEGEND: Purchaser(s) agrees that the Company may place a
restrictive legend on the documents representing the Unit(s), the Note(s) and
the Shares.

Purchaser Initials___________

                                       7

<PAGE>

7 STOP TRANSFER ORDER: Purchaser(s) agree that the Company may place a stop
transfer order with its registrar and stock transfer agent (if any) covering all
documents, or certificates representing the Unit(s), the Note(s) and the Shares.

8 KNOWLEDGE OF RESTRICTIONS UPON TRANSFER OF THE UNITS: Purchaser(s) understands
that the Unit(s), including the Note(s) and the Shares, are not freely
transferable and may in fact be prohibited from sale for an extended period of
time and that, as a consequence thereof, the undersigned must bear the economic
risk of an investment in the Unit(s) for an indefinite period of time and may
have extremely limited opportunities to dispose of the same. Purchaser(s)
understands the Rule 144 of the Commission permits the transfer of "restricted
securities" of the type herein involved only under certain conditions, after and
including the minimum holding period,( which with respect to the shares., will
not begin to run until the exercise of the convertible option and the exercise
of the warrant(s)) and the availability to the public of certain information
concerning the Company.

9. ADDITIONAL DOCUMENTS: Purchaser(s) agrees to execute such other documents and
instruments (if any) as counsel for the Company reasonably deems necessary to
effect the compliance of the issuance of the Unit(s), Note(s), and Share(s) as
may be required by federal and state laws.

10. BINDING EFFECT: Neither this agreement nor any interest herein shall be
assignable by Purchaser(s) without the prior written consent of the Company. The
provisions of this agreement shall be binding upon and inure to the benefit of
the parties hereto, and their respective heirs, legal representatives,
successors, and assigns.

11. REPRESENTATIONS TO SURVIVE DELIVERY: The representations, warranties, and
agreements of the Company and Purchaser(s) contained in this agreement will
remain operative and in full force and effect and will survive the payment of
the purchase price pursuant to Section 1 above and the delivery of documents
representing the Unit(s).

12. GOVERNING LAW: This agreement shall be governed by and construed in
accordance with the laws of the STATE OF NEW YORK, COUNTY OF ROCKLAND, exclusive
of its conflict of laws rules.

Purchaser Initials___________

                                       8

<PAGE>

IN WITNESS WHEREOF, the undersigned has hereunto affixed his, her, or its
signature.

In the Presence of :

-----------------------                              ---------------------------
                                                     BY: PURCHASER(S)

                                                     Address:
                                                            --------------------

                                                     ---------------------------

The Company hereby accepts the purchaser(s) intent to purchase the Unit(s) as
evidenced by this Securities Purchase Agreement and Purchaser(s) Investment
Representation Agreement.

In the Presence of:                                RETRAC MEDICAL, INC.

-----------------------                            ---------------------------
                                                   BY: THOMAS SASSONE
                                                   Title: PRESIDENT CEO

THIS SECURITES PURCHASE AGREEMENT AND NOTE HAS NOT BEEN REGISTERED UNDER THE
SECURITIES ACT OF 1933, AS AMENDED, (THE "ACT") OR ANY STATE SECURITIES LAWS AND
NEITHER THIS NOTE NOR ANY INTEREST THEREIN MAY BE OFFERED, SOLD, TRANSFERRED,
PLEDGED OR OTHERWISE DISPOSED OF EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION
STATEMENT UNDER SUCH ACT OR SUCH LAWS OR AN EXEMPTION FROM REGISTRATION UNDER
SUCH ACT AND SUCH LAWS OR AN EXEMPTION FROM REGISTRATION UNDER SUCH ACT AND SUCH
LAWS WHICH, IN THE OPINION OF COUNSEL SATISFACTORY TO THE COMPANY, IS AVAILABLE.

Purchaser Initials___________

                                       9

<PAGE>

                            PURCHASER(S) INFORMATION

           -----------------------------------------------------------
                       (Please print name(s) in which the
                            Unit(s) are to be issued)

                          -----------------------------
                                Taxpayer I.D. No.

Address:  _________________________________________________________

City: ____________________ State: ______________ Zip Code _____________

Telephone Number  ___________________

Check One:

____  Individual Ownership                  ____  Tenants in Common

____  Other                                 ____  Joint Tenants

Purchaser Initials___________

                                       10

<PAGE>

                                                                       EXHIBIT A

THIS NOTE HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED,
(THE "ACT") OR ANY STATE SECURITIES LAWS AND NEITHER THIS NOTE NOR ANY INTEREST
THEREIN MAY BE OFFERED, SOLD, TRANSFERRED, PLEDGED OR OTHERWISE DISPOSED OF
EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER SUCH ACT OR SUCH
LAWS OR AN EXEMPTION FROM REGISTRATION UNDER SUCH ACT AND SUCH LAWS OR AN
EXEMPTION FROM REGISTRATION UNDER SUCH ACT AND SUCH LAWS WHICH, IN THE OPINION
OF COUNSEL SATISFACTORY TO THE COMPANY, IS AVAILABLE.

                            UNSECURED PROMISSORY NOTE

                                                              NEW CITY, NEW YORK

U.S. $____________

DATE: ____________, 2000

FOR VALUE RECEIVED, the undersigned, RETRAC MEDICAL, INC., a corporation
organized and existing under the laws of the State of Delaware, formerly
Re-Track USA, Inc., with offices at 22 South Main Street, New City, New York
10956 ("Company") hereby promises to pay to ____________________________________
(the "Purchaser(s)"), residing at
___________________________________________________________________, the
principal sum of _________________________________________no/100 United States
Dollars(US$_____________) together with interest thereon computed at the rate of
twelve percent (12%) per annum, from the date hereof until the principal hereof
and all interest thereon shall have been paid. Principal and interest shall be
payable upon the nine (9) month anniversary date from the effective date herein
or on the completion of an Initial Public Offering of the Company's securities
registered with the United States Securities and Exchange Commission ("SEC")
under the Securities Act of 1933 ("Act") (the "IPO").

Upon repayment of this Note, the Company shall issue to the Purchaser(s) a
number of shares (the "Shares") of the Company's common stock, par value $.01,
per share ("Common Stock"), as shall be calculated by dividing the principal
amount of this Note by an amount equal to fifty percent (50%) of the public
offering price of a share of Common Stock offered in the Company's initial
registered public offering under the Act. The Shares shall be "restricted
securities" as such term is defined in Rule 502 of Regulation D promulgated
under the Act, shall be subject to substantial restrictions on any resale or
transfer thereof and the certificate evidencing the Shares shall be imprinted
with a restrictive legend prohibiting the transfer of any such Shares (in form
substantially similar to the restrictive legend imprinted atop the Note).
Commencing twelve months after the completion of the IPO, the Purchaser(s) shall
have one demand registration right with respect to the Shares under the Act and
shall have unlimited "piggy-back" registration rights with respect to the
Shares, all at the Company's expense.

Purchaser Initials___________

                                       11

<PAGE>

The following shall be deemed events of default hereunder:

(a) If any payment shall not be made within ten (10) days after a written notice
of such payment having become due and payable; and

(b) If the Maker shall (i) apply for or consent to the appointment of a
receiver, trustee or liquidator of a substantial part of its assets or property;
(ii) make a general assignment for the benefit of creditors; (iii) be
adjudicated a bankrupt; (iv) file a voluntary petition in bankruptcy or petition
or an answer seeking reorganization, or make a plan with creditors or take
advantage of any bankruptcy, reorganization, insolvency, readjustment of debt,
dissolution or liquidation law or statute now or hereafter in effect or an
answer admitting the material allegations of any petition filed against it in
any proceeding under any such law or statute; or, (v) admit in writing the
Company's inability to pay the Company's debts as they become due; and

(c) If any proceeding against the Company seeking reorganization, arrangement,
composition, adjustment, liquidation, dissolution or similar relief under the
present or any future Federal Bankruptcy Act of other applicable Federal or
state statute, law or regulation shall remain undismissed or continue unstayed
and in effect for any period of forty five (45) days; and

(d) If a court of competent jurisdiction shall enter an order, judgment or
decree appointing a receiver for a substantial part of the assets or properties
of the Company and such order, judgment or decree shall continue unvacated or
unstayed and in effect for a period of forty five (45) days.

Unless the Purchaser(s) otherwise elects, in the Purchaser(s) sole discretion,
upon the occurrence of any such event of default, this Note shall automatically
become immediately due and payable, without further notice or demand, and shall
bear interest from such date until paid in full at the rate of Twelve percent
(12%) per annum.

Notwithstanding any other provision of this Note, interest under this Note shall
not exceed the maximum rate permitted by law; and if any amount is paid under
this Note as interest in excess of such maximum rate, then the amount so paid
will not constitute interest but will constitute a prepayment on account of the
principal amount of this Note. If at any time the interest rate under this Note
would, but the provision of the preceding sentence, exceed the maximum rate
permitted by law, then the outstanding principal balance of this Note shall, on
demand by the Purchaser(s) of this Note, become and be due and payable.

Purchaser Initials___________

                                       12

<PAGE>

All payments of principal and interest shall be made in lawful currency of the
United States of America in immediately available funds before 12:00a.m. New
York City time on the due date thereof at the place and address as provided
herein by the Purchaser(s), or in such other manner or at such other place as
the Purchaser(s) designates in writing.

Except as otherwise expressly provided herein, the Company hereby waives
presentment, demand for payment, dishonor, notice of dishonor, protest and
notice of protest.

The liability of the Company hereunder shall be unconditional. No act, failure
or delay by the Purchaser(s) hereof to declare a default as set forth herein or
to exercise any right or remedy it may have hereunder, or otherwise, shall
constitute a waiver of its rights to declare such default or to exercise any
such right or remedy at such time as it shall determine in its sole discretion.
The Purchaser(s) of this Note may not waive any of its rights except by an
instrument in writing signed by the Purchaser(s).

The Company further agrees to pay all costs of collection, including a
reasonable attorney's fee, in case the principal or any interest thereon is not
paid at the maturity date of this Note.

This Note shall be binding upon the Company, its successors, or assigns.

This Note may not be amended without the written approval of the Purchaser(s).

THIS NOTE AND THE OBLIGATIONS OF THE UNDERSIGNED SHALL BE GOVERNED BY AND
CONSTRUED IN ACCORDANCE WITH THE LAWS OF NEW YORK STATE. FOR PURPOSES OF ANY
PROCEEDING INVOLVING THIS NOTE OR ANY OF THE OBLIGATIONS OF THE UNDERSIGNED, THE
UNDERSIGNED HEREBY SUBMITS TO THE NON-EXCLUSIVE JURISDICTION OF THE COURTS OF
THE STATE OF NEW YORK AND OF THE UNITED STATES HAVING JURISDICTION IN THE COUNTY
OF ROCKLAND, STATE OF NEW YORK AND AGREES NOT TO RAISE AND WAIVES ANY OBJECTION
TO OR DEFENSE BASED UPON THE VENUE OF ANY SUCH COURT OR BASED UPON FORUM NON
CONVENIENS. THE COMPANY CONSENTS TO SERVICE OF PROCESS BY CERTIFIED OR
REGISTERED MAIL AT THE COMPANY'S LAST KNOWN ADDRESS.

In the Presence of                         RETRAC MEDICAL, INC.

_________________________                 By:_____________________________
                                          Name: THOMAS SASSONE
                                          Title: PRESIDENT CEO
Purchaser Initials___________

                                       13

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00019-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00019-of-00352.parquet"}]]